All In Biotech

Drug Trial Radar · NCT01996306

A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC

A Multinational, Randomized, Phase III Study of XELIRI With/Without Bevacizumab Versus FOLFIRI With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Jan 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 650 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

650

Actual

Start

Dec 2, 2013

Primary completion

Nov 20, 2017

Study completion Jun 30, 2018

Sponsor

Lead sponsor
Epidemiological and Clinical Research Information NetworkAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 27, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to determine the non-inferiority of overall survival XELIRI with or without Bevacizumab compared with FOLFIRI with or without Bevacizumab as Second-line therapy in Patient with Metastatic Colorectal Cancer.

Conditions

  • Colorectal Neoplasms
  • Neoplasm Metastasis
  • Intestinal Neoplasms
  • Gastrointestinal Neoplasms
  • Digestive System Neoplasms

Interventions

  • BevacizumabBiological

    5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.

  • CPT-11 (Irinotecan)Drug

    150-180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle.

  • 5-FU BolusDrug

    400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.

  • 5-FU InfusionDrug

    2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.

  • l-LV (dl-LV)Drug

    200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.

  • bevacizumabBiological

    7.5mg/kg IV intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on Day 1 of a 3-week cycle.

  • CPT-11 (Irinotecan)Drug

    150-200 mg/m2 intravenously administered over 90 minutes on day 1 of a 3-week cycle.

  • CapecitabineDrug

    1600mg/m2/day oral on day 1 (evening) to day 15 (morning)of a 3-week cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: Assessed until 1.5 years after the last patient enrolment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NPO Epidemiological and Clinical Research Information Network (ECRIN)

    Kyoto, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.